|
Nuravax Inc, a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced that two oral presentations - the phase 1 clinical results and the phase 2 secondary prevention study design for its licensed lead drug product, the amyloid-beta (Aß) vaccine, AV-1959R - have been accepted at the 18th Clinical Trials on Alzheimer's Disease (CTAD-25) conference, scheduled for December 3–5, 2025 in San Diego, California.
Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer's disease.
Roman Kniazev, CEO of Nuravax, Inc., said, "The MultiTEP platform behind AV-1959R was specifically engineered to overcome immunological tolerance and safely induce strong anti-Aß antibody responses across diverse populations at risk," and he continued, "The phase 1 outcomes may validate decades of translational vaccine research and offer a path forward for active immunization and prevention or mitigation of risk."
The AV-1959R is an adjuvanted, Aß epitope-specific vaccine built on the proprietary MultiTEP platform, designed to induce high levels of antibodies while avoiding autoreactive T cell responses. It is intended for both secondary prevention in individuals with biomarker-positive disease and primary preventive therapy for individuals at elevated risk of Alzheimer's pathology due to known factors, including a family history of the disease, the presence of the APOE4 genotype, mutations in APP, PSEN1, PSEN2, TREM2, and CASP8 genes as well as comorbid conditions (e.g., hypertension, hyperlipidemia, type 2 diabetes mellitus, obesity, etc).
Nuravax is a clinical-stage biotechnology company developing immunotherapy vaccines for neurodegenerative diseases such as Alzheimer's, disease, Parkinson's disease, TBI, and CTE. Focused on early intervention, it leads the clinical, regulatory, and manufacturing efforts for Duvax - a dual-target vaccine licensed from the Institute for Molecular Medicine.
|